Table 5.

Analyses of Overall Survival (OS) for Patients with Metastatic Disease

		Univariable Analyses		Multivariable Analyses*
Patient Characteristic		Hazard Ratio (95% CI)	P-value	Hazard Ratio (95% CI)	P-value
Synchronous Metastases
LN Positive	Yes vs. No	1.5 (0.8, 2.8)	0.20	2.1 (1.1, 4.0)	0.03
Clear Cell	Clear Cell vs. Other	1.2 (0.6, 2.3)	0.68	NI
Metastasectomy**	Yes vs. No	0.8 (0.4, 1.3)	0.35	0.9 (0.5, 1.5)	0.62
ECOG Status***	≥1 vs 0	1.5 (0.8, 2.8)	0.27	1.7 (0.9, 3.5)	0.13
Tumor Stage			0.18		0.11
	T3 vs T1/T2	1.8 (0.8, 4.0)		2.2 (1.0, 4.9)
	T4 vs T1/T2	2.6 (0.9, 7.3)		3.1 (1.0, 9.7)
Age	>55 vs ≤55	1.0 (0.6, 1.7)	0.97	1.2 (0.7, 2.2)	0.54
Asynchronous Metastases
LN Positive	Yes vs No	2.8 (1.1, 7.4)	0.03	3.3 (1.2, 9.2)	0.02
Clear Cell	Clear Cell vs. Other	0.7 (0.2, 2.1)	0.47	NI
Metastasectomy**	Yes vs. No	0.6 (0.2, 1.5)	0.29	0.5 (0.2, 1.4)	0.17
Tumor Stage			0.96	NI
	T3 vs T1/T2	1.2 (0.4, 3.5)
	T4 vs T1/T2	1.1 (0.3, 3.6)
Age	>55 vs ≤55	0.7 (0.3, 1.9)	0.50	1.0 (0.4, 2.6)	0.94

^*There were 53 events among patients with synchronous metastasis so only 5 covariates were included in the multivariate model, with selection based on clinical relevance. For patients with asynchronous metastasis, there were only 19 events so only 3 factors were included in the multivariate model based on clinical relevance.

^**Since patients with and without metastasectomy were matched pairs where the patient without metastasectomy lived at least to the time the metastasectomy was performed, no adjustment is made for metastasectomy occurring after nephrectomy.

^***ECOG performance status was measured at nephrectomy and was not recorded separately at the time of later metastasis diagnosis; therefore it was not included for patients with asynchronous metastasis.